Disparity in bone mineral density of males and females with age

Nusrat Aziz *

Department of Physiology, Faculty of Medicine, Umm Al-Qura University, Makkah 24382, Kingdom of Saudi Arabia.

Publication history: Received on 20 December 2020; revised on 28 December 2020; accepted on 30 December 2020

Article DOI: https://doi.org/10.30574/wjarr.2020.8.3.0504

Abstract

Decline in bone mass with aging leads to osteoporosis and fragility fractures. It has profound effect on the morbidity and health quality of the elderly, creating financial burden on the society.

Usually, age related loss in bone mass goes undiagnosed until a fragility fracture occurs. It was observed that the bone mineral density (BMD) was found to be lesser in females compared to males in all age groups.

There were significant BMD differences between males and females from age 41 yrs and above, BMD declined with age in both males and females. The maximum decline was observed in age group of 41 yrs -50 yrs compared to the control group of 20 yrs-30 yrs.

The decrease in BMD was highly noticeable in females, with osteoporosis from age group 51 yrs-60 yrs. It coincides with peri-menopausal and early after menopause period. In males osteoporosis was not observed until the age of 80yrs, though osteopenia have been observed from 41 yrs onwards.

There is a paramount need of awareness about detrimental effects of aging on BMD in order to bring about necessary lifestyle changes and follow therapeutic measures. This enables us to attain higher peak bone mass and maintain higher bone densities.

Keywords: Osteoporosis; Age; Males; Females, BMD

1. Introduction

Age related bone loss largely goes unnoticed until a fracture occurs. It is one of the leading causes of morbidity. The disability adjusted life years with hip and vertebral fracture were 2496 to 3168 [1,2] with significant reduction in health related quality of life (HRQoL) [3]. The economic cost of osteoporotic fracture $20.3 billion in 2005 in United States of America with projection to $25.3 billion per year by 2025.

The major factors effecting age related bone loss are

- Gender- women have 4 times higher rate of osteoporosis and twice rate of osteopenia than men [5,6]
- Age- Bones attain peak bone mass by the age of 20 years which remains relatively stable for about 15 to 20 yrs. The bones start losing minerals by the age 35- 40 yrs of age.
- Race- Osteoporosis was found to be around 20% and osteopenia in >50% in Asians and Hispanic [7]
- Family History- People with family history of more likely to develop osteoporosis [8].
- Body frame- Individuals with smaller body frame size are more likely to develop osteoporosis.
- Nutritional status- deficiency of calcium and vitamin can increase bone loss.

*Corresponding author Dr.Nusrat Aziz
Department of Physiology, Faculty of Medicine, Umm Al-Qura University, Makkah 24382, Kingdom of Saudi Arabia.

Copyright © 2020 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution License 4.0.
2.1.4. Testosterone

Estrogen decrease with menopause shows 10-year cumulative decrease of 9% in BMD. A 5% per year age decrease in estradiol increases the risk of fracture by 1.5 times [28]. Estrogen decrease osteoclast and osteoblast apoptosis while inhibiting osteoblast differentiation. The net effect is decreased bone resorption. The main source of estrogen in males is the testis, where estrogen is synthetized from testosterone by the action of aromatase. It exerts its beneficial effect on BMD both in males and females. Aromatase deficiency can lead to decreased sex hormone binding globulin (SHBG) with increased free testosterone and increased LH in males. Active free testosterone declines by 2% per year, age 23% by 6% in BMD in males [29,30].

2.1.3. Estrogen

Estrogen decrease with menopause shows 10-year cumulative decrease of 9% in BMD. A 5% per year age decrease in estradiol increases the risk of fracture by 1.5 times [28]. Estrogen decreases osteoclast and osteoblast apoptosis while inhibiting osteoblast differentiation. The net effect is decreased bone resorption. The main source of estrogen in females is the ovaries. In males estrogen is synthesized from testosterone by the action of aromatase. It exerts its beneficial effect on BMD both in males and females. Aromatase deficiency can lead to decreased sex hormone binding globulin (SHBG) with increased free testosterone and increased LH in males. Active free testosterone declines by 2% per year, age 23% by 6% in BMD in males [29,30].

1.2.4. Parathyroid hormone

Parathyroid hormone increases with aging due to primary hyperparathyroidism or secondary to Vit D deficiency and decreasing calcium levels [25]. Parathyroid hormone increases bone resorption by stimulating production of RANK, increasing expression of RANK induced by receptor activator of nuclear factor κB ligand (RANKL) binds to osteoblasts. The PTH–RANKL pathway increases bone formation by positive effect on osteoblast. It increases osteoclastic activity the net effect is decreased BMD in elderly. The hormones affecting bone mineral densities and producing age-related osteoporosis as follows

1.2.3. Growth hormone

Aging shows decrease in growth hormone secretion and insulin like Growth factor-1 (IGF-1). Growth hormone either directly or through IGF-1 increases osteoblast differentiation, activity and survival. Growth hormone can also increase osteoclastic activity therefore increasing bone remodeling [22,23]. IGF-1 is positively associated with BMD in women though the effect is not so evident in males [24,25].

1.2.2. Estrogen

The thyroid hormone increased with aging due to primary hyperparathyroidism or secondary to Vitamin D deficiency and increasing calcium levels [25]. Parathyroid hormone increases bone resorption by stimulating production of RANK, increasing expression of RANKL. It binds to osteoblasts. The PTH–RANKL pathway increases bone formation by positive effect on osteoblast. It increases osteoclastic activity the net effect is decreased BMD in elderly. The hormones affecting bone mineral densities and producing age-related osteoporosis as follows

1.2.1. Estrogen

Decreased size of trabecular bone is higher in females than in males [13]. Increased remodeling at periosteal and endosteal surfaces mainly the trabecular bone. The osteoclasts number and lifespan is increased with lesser differentiation of osteoblasts. The bone remodeling by the bone remodeling unit with bone formation by osteoblasts following a period of resorption by osteoclasts is imbalanced in elderly. The net effect is decreased bone remodeling causing osteoporosis. The differentiation of osteoblasts from mesenchymal stem cells is stimulated by the Wnt/β catenin pathway on pairing with low density lipoprotein-related protein 5 (LRP5) thereby increasing the bone mineral density [17]. LRP5 and β catenin are related protein 5 (LRP5) thereby increasing the bone mineral density [17]. LRP5 and β catenin are increased with aging [11] and have been implicated in stimulation of osteoclastogenesis and bone resorption. 1.2.3. Parathyroid hormone

Parathyroid hormone increases bone resorption by stimulating Parathyroid hormone increases bone resorption by stimulating production of RANK, increasing expression of RANKL. It binds to osteoblasts. The PTH–RANKL pathway increases bone formation by positive effect on osteoblast. It increases osteoclastic activity the net effect is decreased BMD in elderly. The hormones affecting bone mineral densities and producing age-related osteoporosis as follows

1.2.2. Estrogen

The thyroid hormone increased with aging due to primary hyperparathyroidism or secondary to Vitamin D deficiency and increasing calcium levels [25]. Parathyroid hormone increases bone resorption by stimulating production of RANK, increasing expression of RANKL. It binds to osteoblasts. The PTH–RANKL pathway increases bone formation by positive effect on osteoblast. It increases osteoclastic activity the net effect is decreased BMD in elderly. The hormones affecting bone mineral densities and producing age-related osteoporosis as follows

1.2.1. Estrogen

Decreased size of trabecular bone is higher in females than in males [13]. Increased remodeling at periosteal and endosteal surfaces mainly the trabecular bone. The osteoclasts number and lifespan is increased with lesser differentiation of osteoblasts. The bone remodeling by the bone remodeling unit with bone formation by osteoblasts following a period of resorption by osteoclasts is imbalanced in elderly. The net effect is decreased bone remodeling causing osteoporosis. The differentiation of osteoblasts from mesenchymal stem cells is stimulated by the Wnt/β catenin pathway on pairing with low density lipoprotein-related protein 5 (LRP5) thereby increasing the bone mineral density [17]. LRP5 and β catenin are increased with aging [11] and have been implicated in stimulation of osteoclastogenesis and bone resorption.
androgens present in females become half after menopause which may also contribute to post-menopausal bone loss apart from estrogens decline [34].

1.2.5. Dehydroepiandrosterone and dehydroepiandrosterone sulphate from adrenal glands

DHEA and DHEAS decline with aging. DHEA replacement has showed significant improvement in BMD specially in females [35]. The beneficial effect DHEA is due to decreased bone resorption and increased bone formation effects. DHEA acts as precursor for estrogens and androgens and also increases IGF-1 levels. [36].

1.2.6. Follicle stimulating hormone (FSH) and luteinizing hormone (LH)

Aging shows decreased gonadal hormones with increasing levels of FSH and luteinizing hormone (LH). FSH increase 3.5% and LH by 1.1% every year with age in males [32]. FSH increases osteoclast differentiation its activity and survival hence enhancing bone resorption associated with increased expression of RANK and production TNF-α[37]. The levels of FSH increased 5-6 years before menopause in females and may explain bone loss in perimenopausal period [38]. LH rise is also seen in hypogonadism but its role if any in bone loss has not become clear.

1.2.7. Vitamin D

Decreased in skin vitamin D producing capacity, lower dehydrocholesterol levels impaired kidney function and decrease conversion of 25(OH)D to 1,25(OH)2D3 has been seen in elderly [39]. Vitamin D deficiency decreases intestinal and renal calcium absorption. It has anabolic effect on bone by increasing mineralization of bones and stimulating osteoblast differentiation by increased expression of osteoblast specific element Osf2/Cbfa1 [40,41]. However vitamin D can also cause increased resorption by increasing differentiation and activity of osteoclasts thus stimulating bone remodeling [42].

1.2.8. Cortisol

With aging process the glucocorticoids secretion increases. Glucocorticoids in normal physiological levels increase bone mass by up regulation of Wnt/β-catenin signaling. The glucocorticoids cause osteoblast apoptosis and decreased survival by increasing reactive oxygen species and decreased mitochondrial activity [43]. Glucocorticoids increase Cathepsin k release by autophagic osteoblasts and which can increase bone matrix degradation [44]. It further decreases bone hydration, vascularity and blood flow [45].

1.2.9. Thyroid stimulating hormone (TSH)

Thyroid stimulating hormone decreases bone remodeling by inhibiting osteoblasts differentiation and collagen-1 along with decrease in osteoclast differentiation [46]. Aging is observed to decrease thyroid function with 3-6% people in > 60 years age group show subclinical hypothyroidism with elevated TSH [47]. Its overtreatment or associated iodine deficiency can produce subclinical hyperthyroidism with increased TSH and more risk of fractures [48].

2. Material and methods

A crosssectional study was done in adult males and females from 20 to 80 years of age.

Bone mineral densities of 180 male and female participants were checked, during free BMD camps, conducted at Hyderabad India. Gender distribution included 90 males and 90 females. Their age, weight, height, body surface area and Body mass index was recorded. Inclusion criteria were healthy subjects free of any endocrine disorder or bone related chronic disease. Exclusion criteria: subjects suffering from bone disorders or any chronic condition affecting bones such as diabetics mellitus, gout rheumatoid arthritis etc were excluded. Subjects who were on drugs such as corticosteroids, thyroxin and hormone replacement therapy were also excluded. The subjects were divided into groups depending upon their age and sex. Their height, weight, body mass index and BMD were taken and analyzed. The participants were explained about the study and informed consent was taken.

DEXA – The bone mineral density was found with Dual Energy X-ray Absorptiometry (DEXA). This technique uses two types of X-ray beams, one is absorbed by soft tissue and the other by bone. It has very low levels of radiation. The DEXA test gives result in two variables that is T Score and Z score. The T score is comparison BMD in standard deviation with that of young adult of 30 years of age while the Z score is the comparison of BMD with a healthy adult of same age and sex. The DEXA test can measure BMD with 2-4% precision [49]. The GE Lunar Achilles Express Densitometer Machine was used for the BMD measurement. The T scores values for the BMD interpretation is taken in terms of Standard deviation (SD) from normal young adult mean. The criteria for interpretation of bone loss is given in table 1

431
Table 1 T score and its interpretation for bone mineral density

| T Score     | Interpretation |
|-------------|----------------|
| -1 to 1 SD  | Normal         |
| -1 to -2.49 SD | Osteopenia   |
| <- 2.5 SD   | Osteoporosis   |

2.1.1. Statistics

The data was analyzed and tabulated according age group and gender. Statistical studies were done to find out the mean with the standard deviation, standard error and 95% confidence intervals of age and BMD. t-tests were done to compare the means between different age groups of same gender and different gender.

3. Results

Bone mineral densities declined with age in both the genders as shown in Table 2. The mean BMD was lesser in females compared to males in all age groups. The disparity in BMD among the genders that is the T score for BMD is greater from age group of 41-50yrs with statistical significance. In the younger age groups the decreased BMD in females than males was not statistically significant. The mean BMD in males and females with increasing age is depicted in Bar diagram (fig 1).

Table 2 BMD in different age groups of males and females and comparison between two genders

| Age group          | Mean | SD | SE | 95% CI        | t-value | p-value |
|--------------------|------|----|----|---------------|---------|---------|
|                    |      |    |    | LL            | UL      |         |
|                    |      |    |    |               |         |         |
| 20-30 years        |      |    |    |               |         |         |
| Males              | Age  | 25 | 3  | 0.7           | 1       | 23      |
|                    | SD   | -0.4| 3  | 0.2           | 2       |
|                    | SE   | 1  | 0.2| 23            | 0.8     |
|                    | 95% CI|     |    | 26            | 0.05    |
|                    | t-value|    |    | 1.7          | p>0.05  |
| Females            | Age  | 25 | 2  | 0.9           | 1       | 24      |
|                    | SD   | -0.9| 2  | 0.2           | 2       |
|                    | SE   | 1  | 0.2| 24            | -1.4    |
|                    | 95% CI|     |    | 26            | 0.4     |
|                    | t-value|    |    | 1.7          | p>0.05  |
| 31-40 years        |      |    |    |               |         |         |
| Males              | Age  | 34 | 3  | 0.7           | 1       | 33      |
|                    | SD   | -0.8| 3  | 0.2           | 2       |
|                    | SE   | 1  | 0.2| 33            | -1.2    |
|                    | 95% CI|     |    | 36            | -0.4    |
|                    | t-value|    |    | 1.9          | p>0.05  |
| Females            | Age  | 35 | 3  | 0.6           | 1       | 33      |
|                    | SD   | -1.2| 3  | 0.2           | 2       |
|                    | SE   | 1  | 0.2| 33            | -1.5    |
|                    | 95% CI|     |    | 36            | -0.8    |
|                    | t-value|    |    | 1.9          | p>0.05  |
| 41-50 years        |      |    |    |               |         |         |
| Males              | Age  | 44 | 3  | 1.2           | 1       | 43      |
|                    | SD   | -1.6| 3  | 0.3           | 2       |
|                    | SE   | 1  | 0.3| 43            | -1.7    |
|                    | 95% CI|     |    | 48            | -1.5    |
|                    | t-value|    |    | 2            | P<0.05  |
| Females            | Age  | 46 | 3  | 1.2           | 1       | 44      |
|                    | SD   | -2.1| 3  | 0.3           | 2       |
|                    | SE   | 1  | 0.3| 44            | -2.7    |
|                    | 95% CI|     |    | 48            | -1.5    |
|                    | t-value|    |    | 2            | P<0.05  |
| 51-60 years        |      |    |    |               |         |         |
| Males              | Age  | 54 | 3  | 1.4           | 1       | 53      |
|                    | SD   | -1.4| 3  | 0.8           | 2       |
|                    | SE   | 1  | 0.8| 53            | -1.9    |
|                    | 95% CI|     |    | 56            | -0.9    |
|                    | t-value|    |    | 3            | P=0.001 |
| Females            | Age  | 55 | 3  | 1.4           | 1       | 53      |
|                    | SD   | -2.5| 3  | 0.7           | 2       |
|                    | SE   | 1  | 0.7| 53            | -2.8    |
|                    | 95% CI|     |    | 56            | -2.1    |
|                    | t-value|    |    | 3            | P=0.001 |
| 61-70 years        |      |    |    |               |         |         |
| Males              | Age  | 66 | 3  | 1.4           | 1       | 64      |
|                    | SD   | -2  | 3  | 0.8           | 4       |
|                    | SE   | 1  | 0.8| 64            | 0.4     |
|                    | 95% CI|     |    | 67            | -2.8    |
|                    | t-value|    |    | 3.3          | P<0.001 |
| Females            | Age  | 65 | 3  | 1.4           | 1       | 64      |
|                    | SD   | -2.8 | 3  | 0.9           | 4       |
|                    | SE   | 1  | 0.9| 64            | 0.1     |
|                    | 95% CI|     |    | 67            | -3.1    |
|                    | t-value|    |    | 3.3          | P<0.001 |
| 71-80 years        |      |    |    |               |         |         |
| Males              | Age  | 74 | 2  | 1             | 0       | 73      |
|                    | SD   | -1.9| 2  | 0.7           | 3       |
|                    | SE   | 1  | 0.7| 73            | 0.3     |
|                    | 95% CI|     |    | 76            | -2.6    |
|                    | t-value|    |    | 3            | P<0.001 |
| Females            | Age  | 74 | 2  | 0.9           | 0       | 72      |
|                    | SD   | -3.4| 2  | 0.7           | 3       |
|                    | SE   | 0.9| 0.7| 72            | 0.2     |
|                    | 95% CI|     |    | 75            | -3.9    |
|                    | t-value|    |    | 4            | P<0.001 |
Figure 1 Mean BMD in males and females in different age groups

Table 3 Change in BMD with age and its comparison with BMD of control group in females

| Age Group          | Mean Age | Mean BMD | t value | p value |
|--------------------|----------|----------|---------|---------|
| 20-30 yrs (control)| 25±2     | -0.9±0.9 |         |         |
| 31-40 yrs          | 35±3     | -1.2±0.6 | 1.3     | p>0.05  |
| 41-50 yrs          | 46±3     | -2.1±1   | 3.0     | P<0.01  |
| 51-60 yrs          | 55±2.7   | -2.5±0.7 | 5.3     | P<0.001 |
| 61-70 yrs          | 65±3.4   | -2.8±0.5 | 7.5     | P<0.001 |
| 71-80 yrs          | 74±3     | -3.4±0.9 | 7.7     | P<0.001 |

Figure 2 Mean BMD with different age groups in females

Analysis of BMD within females (Table 3) showed the decline in bone mass to osteoporotic levels from age above 51 years and osteopenia in age groups 31 to 40 and 41-50 years. T tests were done to compare BMD with that of control group that is 20-30 years of age. The decline in BMD compared to y control was statistically significant from 41 years
and above. There was rapid decline in mean BMD from age group 31-40 to 41-50 corresponding perimenopausal period. After which there was decline in BMD of 16-21% with each 10 year increase in age from the age of 41 years. Strong negative correlation was found between mean age and mean BMD in females which was statistically significant. The progressive lowering in BMD with age is depicted in the line diagram (fig 2).

BMD in male participants showed osteopenic changes from ages of 41 and above as shown in Table 4. In males also the maximum decline in BMD was from age group 31-40 to 41-50. There was significant decline in BMD in age group of 41-50 years compared to control. Pearson’s correlation showed statistically significant negative correlation between mean age and mean BMD in male participants too. Osteoporosis with a mean BMD of a T score of below -2.5SD was not found even till the age group of 71-80 years in males. The decline in BMD with age in males is shown in line diagram (fig 3) given below.

Table 4 Change in BMD with age and its comparison with BMD of control group in males.

| Age Group   | Mean Age | Mean BMD | t value | p value |
|-------------|----------|----------|---------|---------|
| 20-30 yrs (control) | 25±3     | -0.4±0.7 |         |         |
| 31-40 yrs   | 34±2     | -0.8±0.7 | 1.6     | p>0.05  |
| 41-50 yrs   | 44±3     | -1.6±1.2 | 2.4     | P<0.05  |
| 51-60 yrs   | 54±3.2   | -1.4±0.8 | 3.7     | P=0.001 |
| 61-70 yrs   | 66±3     | -2 ±1.4  | 3.9     | P<0.001 |
| 71-80 yrs   | 74±2     | -1.9±1.0 | 4.9     | P<0.001 |

Figure 3 Mean BMD with different age groups in males

The mean height, mean weight, body surface area (BSA) and body mass index (BMI) were calculated as shown in Table 5. The BMI appeared to decrease progressively with age but there was no significant correlation between the BMI and mean age. No significant correlation was found between BMI and mean BMD also.
Table 5: Body surface area and body mass index of males and females of different age groups

| Age Group (Yrs) | Males | Females |
|-----------------|-------|---------|
|                 | Mean Height | Mean Weight | BSA | BMI | Mean Height | Mean Weight | BSA | BMI |
| 20-30           | 162.66       | 59.73     | 1.62 | 22.7 | 154.33       | 54.66     | 1.52 | 23  |
| 31-40           | 164.66       | 75.6      | 1.9  | 28.1 | 155.73       | 62.53     | 1.63 | 26  |
| 41-50           | 161.73       | 76.6      | 1.82 | 29.55| 157.93       | 60.06     | 1.62 | 24.46|
| 51-60           | 160.93       | 77.8      | 1.87 | 30.03| 153.26       | 60.6      | 1.62 | 25.89|
| 61-70           | 157.33       | 61.13     | 1.64 | 24.8 | 149.3        | 57.2      | 1.52 | 25.77|
| 71-80           | 156.2        | 52.2      | 1.52 | 21.45| 144          | 38.71     | 1.26 | 18.67|

4. Discussion

Bones undergo structural and functional decline with age. Osteoporosis with aging is a major problem in society with increased morbidity, mortality and decreased health-related quality of life. The propensity for fragility fractures increases tremendously with age-related bone loss. The risk of fragility fracture increases by 1.5-2.5% with each 1SD fall in BMD [50].

This study has shown the detrimental effect of age on BMD. The south Asian individuals show relatively lower BMD compared to western standards as has been in our control group attributing to ethnic differences. The peak bone mass as checked by the control group of 20-30 years of age was higher in males than females [51]. The osteopenia changes in males arise 10 years later in males than females. Osteoporotic changes females were observed from age group of 41-50 years similar to study by Lee et al [52]. Osteopenic changes in 31-40 yrs. and osteoporotic by 41-50 years can be attributed to perimenopausal and early post-menopausal changes [53] as the mean age of menopause in Asians is 46.2 years in the Indian population [54]. The decline in BMD females was rapid between age group 31-40 to 41-50 and thereafter a slower decline of around 19-21% was observed with each 10 year increase in age. Bone loss starts 5-6 years before menopause and continues after, due to increase in FSH from before and loss of estrogens after menopause apart from other physiological changes. Osteoporotic changes were not observed in males even till 80 years of age as also observed by Alswat in his study [5]. The decline in BMD in males was more from age group 31-40 to 41-50 years. After which the decrease in BMD in males was gradual to reach a mean BMD around -1.9 by age 80 near to the similar BMD values by Kruger et al findings [55] with greater fracture risk beyond 80 years.

5. Conclusion

Osteoporotic fractures lead to considerable financial burden on the individual and the society. Despite being so common it has been largely under-diagnosed. Postmenopausal women in particular are greatly susceptible to its deleterious effects. Greater knowledge of age-related bone loss its prevention and management should be spread among the society. More rigorous screening for BMD with appropriate lifestyle and therapeutic changes in the early stages is the need of the hour.

Compliance with ethical standards

Acknowledgments

I am thankful to my family for their continual support and encouragement.

Disclosure of conflict of interest

There is no conflict of interest and no funding was taken.

Statement of informed consent

Informed consent was obtained from all individual participants included in the study.
References

[1] Bae G, Kim E, Kwon HY, Ha YC, An J, Park J, Yang H. Burden of Osteoporotic Fractures Using Disability-Adjusted Life Years in South Korea. Asia Pacific Journal of Public Health. 2020; 32(2–3): 111–117.

[2] World Health Organization. WHO scientific group on the assessment of osteoporosis at the primary health care level: summary meeting report. Brussels, Belgium; Geneva, Switzerland: World Health Organization. 2007.

[3] Salaffi F, Cimmino MA, Malavolta N, Carotti M, Di Matteo L, Scendoni P, Grassi W, Italian Multicentre Osteoporotic Fracture Study Group. The burden of prevalent fractures on health-related quality of life in postmenopausal women with osteoporosis: the IMOF study. The Journal of rheumatology. 2007; 34(7): 1551–1560.

[4] Roche JJ, Wenn RT, Sahota O, Moran CG. Effect of comorbidities and postoperative complications on mortality after hip fracture in elderly people: prospective observational cohort study. BMJ. 2005; 331(7529): 1374.

[5] Alsawt KA. Gender Disparities in Osteoporosis. Journal of clinical medicine research. 2017; 9(5): 382–387.

[6] Lee J, Lee S, Jang S, Ryu OH. Age-Related Changes in the Prevalence of Osteoporosis according to Gender and Skeletal Site: The Korea National Health and Nutrition Examination Survey 2008-2010. Endocrinology and metabolism (Seoul, Korea). 2013; 28(2): 180–191.

[7] Thomas, Patricia A. MD, MA, FCAP Racial and Ethnic Differences in Osteoporosis, Journal of the American Academy of Orthopaedic Surgeons: 15: S26-S30.

[8] Bijelic R, Milicevic S, Balaban J. The Influence of Non-preventable Risk Factors on the Development of Osteoporosis in Postmenopausal Women. Materia socio-medica. 2019; 31(1): 62–65.

[9] Goldman H, Mcfarlin S, Cooper D, Thomas C, Clement J. Ontogenetic Patterning of Cortical Bone Microstructure and Geometry at the Human Mid-Shaft Femur. Anat Rec. 2009; 292: 48–64.

[10] Chen J, Liu C, You L, Simmons. Boning up on Wolff's Law: Mechanical regulation of the cells that make and maintain bone. Journal Of Biomechanics. 2010; 43(1): 108-118.

[11] Burr DB. Changes in bone matrix properties with aging. Bone. 2019; 120: 85–93.

[12] Rochefort G, Pallu S, Benhamou C. Osteocyte: the unrecognized side of bone tissue. Osteoporosis International. 2010; 21(9): 1457-1469.

[13] Appelman-Dijkstra NM, Papapoulos SE. Modulating Bone Resorption and Bone Formation in Opposite Directions in the Treatment of Postmenopausal Osteoporosis. Drugs. 2015; 75(10): 1049–1058.

[14] Compton J. Age-Related Changes in Bone Remodelling and Structure in Men: Histomorphometric Studies. Journal Of Osteoporosis. 2011; 1-4.

[15] Aaron J, Makins N, Sagrejya K. The Microanatomy of Trabecular Bone Loss in Normal Aging Men and Women. Clinical Orthopaedics And Related Research, 1987; 215:

[16] Boskey A, Coleman R. Aging, Bone. Journal Of Dental Research. 2010; 89(12): 1333-1348.

[17] Norwitz N, Mota A, Misra M, Ackerman K. LRPS5, Bone Density, and Mechanical Stress: A Case Report and Literature Review. Frontiers In Endocrinology. 2019; 10.

[18] Wang Y, Liu Y, Ma JX, Li BX, Li YK. Zhonghua fu chan ke za zhi. 2011; 46(10): 769–772.

[19] Kamiński A, Karasiewicz M, Bogacz A, Dziekan K, Seremak-Mrozikiewicz A, Czerny B. The importance of the Wnt/β-catenin pathway and LRP5 protein in bone metabolism of postmenopausal women. Advances In Clinical And Experimental Medicine. 2019; 28(2): 179-184.

[20] Barrera G, Pizzimenti S, Daga M, Dianzani C, Arcaro A, Cetrangolo G. et al. Lipid Peroxidation-Derived Aldehydes, 4-Hydroxynonenal and Malondialdehyde in Aging-Related Disorders. Antioxidants. 2018; 7(8): 102.

[21] Ginaldi L, Di Benedetto MC, De Martinis M. Osteoporosis, inflammation and ageing. Immunity & ageing. 2005;

[22] DiGirolamo DJ, Mukherjee A, Fulzele K, Gan Y, Cao X, Frank SJ, Clemens TL. Mode of growth hormone action in osteoblasts. The Journal of biological chemistry. 2007; 282(43): 31666–31674.

[23] Olney RC. Regulation of bone mass by growth hormone. Medical and pediatric oncology. 2003; 41(3): 228–234.

[24] Langlois JA, Rosen CJ, Visser M, et al. Association between insulinlike growth factor I and bone mineral density in older women and men: the Framingham Heart Study. J Clin Endocrinol Metab. 1998; 83: 4257–4262
Van Varsseveld N, Sohl E, Drent M, Lips P. Gender-Specific Associations of Serum Insulin-Like Growth Factor-1 With Bone Health and Fractures in Older Persons. The Journal Of Clinical Endocrinology & Metabolism. 2015; 100(11): 4272–4281.

Cannarella R, Barbagallo F, Condorelli RA, Aversa A, La Vignera S, Calogero AE. Osteoporosis from an Endocrine Perspective: The Role of Hormonal Changes in the Elderly. Journal of clinical medicine. 2019; 8(10): 1564.

Cauley JA. Estrogen and bone health in men and women. Steroids. 2015; 99(Pt A): 11–15.

Hammes S, Levin E. Impact of estrogens in males and androgens in females. Journal Of Clinical Investigation. 2019; 129(5): 1818-1826.

Miedlich S, Karamooz N, Hammes S. Aromatase deficiency in a male patient - Case report and review of the literature. Bone. 2016; 93: 181-186.

Dudek P, Kozakowski J, Zgliczyński W. Late-onset hypogonadism. Przegląd menopauzalny = Menopause review. 2017; 16(2): 66–69.

Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, Bremner WJ, McKinlay JB. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. The Journal of clinical endocrinology and metabolism. 2002; 87(2): 589–598.

Wiren KM, Zhang XW, Olson DA, Turner RT, Iwaniec UT. Androgen prevents hypogonadal bone loss via inhibition of resorption mediated by mature osteoblasts/osteocytes. Bone. 2012; 51(5): 835–846.

Rothman MS, Carlson NE, Xu M, Wang C, Swerdloff R, Lee P, Wieman ME. Reexamination of testosterone, dihydrotestosterone, estradiol and estrone levels across the menstrual cycle and in postmenopausal women measured by liquid chromatography–tandem mass spectrometry. Steroids. 2011; 76(1-2): 177-182.

Jankowski CM, Wolfe P, Schmiegé SJ, Nair KS, Khosla S, McVey DM, Ranasinghe DJ, Lui Y. The Relationship between Follicle-stimulating Hormone and Bone Health: Alternative Explanation for Bone Loss beyond Oestrogen?. International journal of medical sciences. 2018; 15(12): 1373–1383.

Randolph JF Jr, Zheng H, Sowers MR, Crandall C, Crawford S, Gold EB. et al. Change in follicle-stimulating hormone and estradiol across the menopausal transition: effect of age at the final menstrual period. J Clin Endocrinol Metab. 2011; 96: 746–54.

Francis RM., Peacock M, Barkworth SA. Renal impairment and its effects on calcium metabolism in elderly women. Age Ageing. 1984; 13: 14–20.

Eisman JA, Bouillion R. Vitamin D: direct effects of vitamin D metabolites on bone: lessons from genetically modified mice. BoneKEy reports. 2014; 3: 499.

Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: A Transcriptional Activator of Osteoblast Differentiation. Cell. 1997; 89(5): 747-754.

Zarei A, Morovat A, Javaid K, Brown CP. Vitamin D receptor expression in human bone tissue and dose-dependent activation in resorbing osteoclasts. Bone Research. 2016; 4(1).

Chen YH, Peng SY, Cheng MT, Hsu YP, Huang ZX, Cheng WT, Wu SC. Different susceptibilities of osteoclasts and osteoblasts to glucocorticoid-induced oxidative stress and mitochondrial alterations. Chin J Physiol. 2019; 62: 70-9.

Jia J, Yao W, Guan M, Dai W, Shahnazari M, Kar R, Bonevald L, Jiang JX, Lane NE. Glucocorticoid dose determines osteocyte cell fate. The FASEB Journal. 2011; 25: 3366-3376.

Lane NE. Glucocorticoid-Induced Osteoporosis: New Insights into the Pathophysiology and Treatments. Curr Osteoporos Rep. 2019; 17: 1–7.

Abe E, Marians R, Yu W, Wu X, Ando T, Li Y. et al. TSH Is a Negative Regulator of Skeletal Remodeling. Cell. 2003; 115(2): 151-162.
[46] Gesing A. The thyroid gland and the process of aging. Thyroid Research. 2015; 8(Suppl 1): A8.

[47] Blum MR, Bauer DC, Collet TH, Fink HA, Cappola AR, da Costa BR, Wirth CD, Peeters RP, Åsvold BO, den Elzen WP, Luben RN, Imaizumi M, Bremner AP, Gogakos A, Eastell R, Kearney PM, Strotmeyer ES, Wallace ER, Hoff M, Ceresini G. Thyroid Studies Collaboration Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA. 2015; 313(20): 2055–2065.

[48] Wahner HW, Fogelman Ignac. The evaluation of osteoporosis: dual energy absorptiometry in clinical practice, Martin Dunitz, Ch. 1994; 3(23).

[49] Marshall Deborah, Johnell Olof, Wedel Hans. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures BMJ. 1996; 312: 1254.

[50] Kaushal N, Vohora D, Jalali RK, Jha S. Prevalence of osteoporosis and osteopenia in an apparently healthy Indian population - a cross-sectional retrospective study. Osteoporosis and Sarcopenia. 2018; 4(2): 53-60.

[51] Lee J, Lee S, Jang S, Ryu OH. Age-Related Changes in the Prevalence of Osteoporosis according to Gender and Skeletal Site: The Korea National Health and Nutrition Examination Survey 2008-2010. Endocrinology and metabolism (Seoul, Korea). 2013; 28(3): 180–191.

[52] Finkelstein JS, Brockwell SE, Mehta V, Greendale GA, Sowers MR, Ettinger B, Lo JC, Johnston JM, Cauley JA, Danielson ME, Neer RM. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. The Journal of clinical endocrinology and metabolism. 2008; 93(3): 861–868.

[53] Ahuja M. Age of menopause and determinants of menopause age: A PAN India survey by IMS. Journal of mid-life health. 2016; 7(3): 126–131.

[54] Kruger MC, Todd JM, Schollum LM, et al. Bone health comparison in seven Asian countries using calcaneal ultrasound. BMC Musculoskelet Disord. 2013; 14: 81.

[55] Cummings SR, Caithon PM, Ensrud KE, Cauley JA, Fink HA, Orwoll ES. BMD and Risk of Hip and Nonvertebral Fractures in Older Men: A Prospective Study and Comparison With Older Women. J Bone Miner Res. 2006; 21: 1550-1556.